Futility analysis performed of the phase II combination study with birinapant and Keytruda® in colorectal cancer patients
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces today that the independent safety committee (IDMC) for the phase II study of birinapant in combination with pembrolizumab (Keytruda®) in patients with MSS colorectal cancer has performed the planned futility analysis. The primary objective of the phase II study was an improved clinical response to treatment measured as 20% ORR (Overall Response Rate). IDMC's recommendation is that the study should be terminated as the analysis indicates that it is unlikely that the study's objectives will be met. Medivir has therefore decided